Personalized choice of maintenance therapies in non-small-cell lung cancer

Current Oncology

Volumn 19, Issue S1, 2012, Pages S64-S72

  Blais, N ^a   Corrales rodriguez L ^b  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b HOSPITAL SAN JUAN DE DIOS   (Costa Rica)

Author keywords

Adenocarcinoma; chemotherapy; early second line; maintenance; nsclc; targeted therapy

Indexed keywords

EID: 85027425231     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.19.1068     Document Type: Article

References (40)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: Globocan 2008. Int J Cancer 2010;127:2893–917.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153–6.
3. Fong KM, Yang IA, Zimmerman PV, Bowman RV. Cochrane systematic reviews of treatments for lung cancer. Respir Med 2005;99:1071–8.
4. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-Small Cell Lung Cancer Collaborative Group. BMJ 1995;311:899–909.
5. Schiller JH, Harrington D, Belani CP, et al. on behalf of the Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92–8.
6. Scagliotti GV, Parikh P, von Pawel J, et al. Phase iii study comparing cisplatin plus gemcitabine with cisplatin plus peme-trexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543–51.
7. Gridelli C, Maione P, Rossi A, et al. Potential treatment options after first-line chemotherapy for advanced nsclc: maintenance treatment or early second-line? Oncologist 2009;14:137–47.
8. Ellis PM, Blais N, Soulieres D, et al. A systematic review and Canadian consensus recommendations on the use of biomarkers in the treatment of non-small cell lung cancer. J Thorac Oncol 2011;6:1379–91.
9. Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to nsclc histology: a review of two phase iii studies. Oncologist 2009;14:253–63.
10. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase ii trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184–91.
11. Genentech. Avastin (Bevacizumab) [prescribing information]. San Francisco, CA: Genentech; 2011. [Available online at: http://www.gene.com/gene/products/information/pdf/avastin-prescribing.pdf; cited April 4, 2012]
12. D’Angelo SP, Pietanza MC, Johnson ML, et al. Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas. J Clin Oncol 2011;29:2066–70.
13. Keedy VL, Temin S, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line egfr tyrosine kinase inhibitor therapy. J Clin Oncol 2011;29:2121–7.
14. Bergethon K, Shaw AT, Ignatius Ou SH, et al. ROS1 rear-rangements define a unique molecular class of lung cancers. J Clin Oncol 2012;30:863–70.
15. Belani CP, Barstis J, Perry MC, et al. Multicenter, randomized trial for stage iiiB or iv non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol 2003;21:2933–9.
16. Westeel V, Quoix E, Moro–Sibilot D, et al. Randomized study of maintenance vinorelbine in responders with advanced non-small-cell lung cancer. J Natl Cancer Inst 2005;97:499–506.
17. Fidias PM, Dakhil SR, Lyss AP, et al. Phase iii study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 2009;27:591–8.
18. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374:1432–40.
19. Brodowicz T, Krzakowski M, Zwitter M, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase iii trial. Lung Cancer 2006;52:155–63.
20. Belani CP, Waterhouse DM, Ghazal H, et al. Phase iii study of maintenance gemcitabine (g) and best supportive care (bsc) versus bsc, following standard combination therapy with gemcitabine-carboplatin (g-cb) for patients with advanced non-small cell lung cancer (nsclc) [abstract 7506]. J Clin Oncol 2010;28:. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=7 4&abstractID=51201; cited April 2, 2012]
21. Perol M, Chouaid C, Milleron BJ, et al. Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced nsclc: ifct-gfpc 0502 phase iii study [abstract 7507]. J Clin Oncol 2010;28:. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstract ID=43861; cited April 2, 2012]
22. Paz–Ares LG, De Marinis F, Dediu M, et al. paramount: phase iii study of maintenance pemetrexed (Pem) plus best supportive care (bsc) versus placebo plus bsc immediately following induction treatment with Pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (nsclc) [abstract CRA7510]. J Clin Oncol 2011;29(suppl);. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstract ID=78420; cited April 2, 2012]
23. Barlesi F, de Castro J, Dvornichenko V, et al. avaperl (MO22089): final efficacy outcomes for patients (pts) with advanced non-squamous non-small cell lung cancer (nsnsclc) randomised to continuation maintenance (mtc) with bevaci-zumab (bev) or bev + pemetrexed (pem) after first-line (1l) bev-cisplatin (cis)-pem treatment (Tx) [abstract 34LBA]. Eur J Cancer 2011;47:16.
24. Miller VA, O’Connor P, Soh C, Kabbinavar F on behalf of the atlas Investigators. A randomized, double-blind, placebo-controlled, phase iiib trial (atlas) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (nsclc) [abstract LBA8002]. J Clin Oncol 2009;27:. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstract ID=30819; cited April 2, 2012]
25. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521–9.
26. Perol M, Chouaid C, Milleron BJ, et al. Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy in advanced nsclc: ifct–gfpc 0502 phase iii study. [abstract 7507]. J Clin Oncol 2010;28:. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstract ID=43861; cited April 2, 2012]
27. Gaafar RM, Surmont V, Scagliotti G, et al. A double-blind, randomized, placebo-controlled phase iii intergroup study of gefitinib (g) in patients (pts) with advanced nsclc, non-progressing after first-line platinum-based chemotherapy (eortc 08021-ilcp 01/03) [abstract 7518]. J Clin Oncol 2010;28:. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstract ID=43827; cited April 2, 2012]
28. Takeda K, Hida T, Sato T, et al. Randomized phase iii trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (wj-tog 0203). J Clin Oncol 2010;28:753–60.
29. Zhang L, Shenglin M, Song X, et al. Efficacy, tolerability, and biomarker analyses from a phase iii, randomized, place-bo-controlled, parallel group study of gefitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer (nsclc; inform; c-tong 0804) [abstract LBA7511]. J Clin Oncol 2011;29:. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_ detail_view&confID=102&abstractID=78381; cited April 2, 2012]
30. Zhang X, Zang J, Xu J, et al. Maintenance therapy with continuous or switch strategy in advanced non-small cell lung cancer: a systematic review and meta-analysis. Chest 2011;140:117–26.
31. Scagliotti GV, Ceppi P, Capelletto E, Novello S. Updated clinical information on multitargeted antifolates in lung cancer. Clin Lung Cancer 2009;10(suppl 1):S35–40.
32. Peterson P, Park K, Fossella F, Gatzemeier U, John W, Sca-gliotti G. Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase iii trial of pemetrexed vs. docetaxel in previously treated patients with advanced non-small cell lung cancer (nsclc): P2–328 [abstract]. J Thorac Oncol 2007;2(suppl 4):S851.
33. Belani CP, Brodowicz T, Ciuleanu T, et al. Maintenance peme-trexed (Pem) plus best supportive care (bsc) versus placebo (Plac) plus bsc: a randomized phase iii study in advanced non-small cell lung cancer (nsclc) [abstract CRA8000]. J Clin Oncol 2009;27:. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view &confID=65&abstractID=33019; cited April 2, 2012]
34. Patel JD, Bonomi P, Socinski MA, et al. Treatment rationale and study design for the PointBreak study: a randomized, open-label phase iii study of pemetrexed/carboplatin/bevaci-zumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage iiib or iv nonsquamous non-small-cell lung cancer. Clin Lung Cancer 2009;10:252–6.
35. Kabbinavar FF, Miller VA, Johnson BE, O’Connor PG, Soh C on behalf of the atlas Investigators. Overall survival (os) in atlas, a phase iiib trial comparing bevacizumab (b) therapy with or without erlotinib (e) after completion of chemotherapy (chemo) with b for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (nsclc) [abstract 7526]. J Clin Oncol 2010;28:. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=74&abstract ID=54084; cited April 2, 2012]
36. Sandler A, Gray R, Perry MC, et al. Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542–50.
37. Reck M, von Pawel J, Zatloukal P, et al. Phase iii trial of cis-platin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: avail. J Clin Oncol 2009;27:1227–34.
38. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (flex): an open-label randomised phase iii trial. Lancet 2009;373:1525–31.
39. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. on behalf of the National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123–32.
40. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase iii study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the tax 326 study group. J Clin Oncol 2003;21:3016–24.